Health Journal Online

Category: Diseases & Conditions

  • Nara Organics Formula Recall: Infant Botulism Cases Rise to 4, FDA Confirms Pathogen in Open Can

    Nara Organics Formula Recall: Infant Botulism Cases Rise to 4, FDA Confirms Pathogen in Open Can

    Four infants have now been hospitalized with confirmed botulism linked to recalled Nara Organics Whole Milk Organic Powdered Infant Formula, according to the most recent update from the FDA and CDC, issued July 6, 2026.

    All four infants required hospitalization and were treated with BabyBIG — the only FDA-approved treatment for infant botulism, available exclusively through the California Department of Public Health’s Infant Botulism Treatment and Prevention Program (IBTPP). No deaths have been reported.

    Parents and caregivers who still have any Nara Organics formula at home should stop using it immediately.

    Why This Matters

    Infant botulism is a rare but potentially fatal illness that occurs in babies — primarily those under 12 months of age — when Clostridium botulinum spores are ingested and produce a toxin inside the infant’s immature digestive system. The toxin attacks the nervous system, causing progressive muscle weakness that can lead to breathing failure if untreated.

    Unlike botulism in adults, which can result from a single contaminated meal, infant botulism requires only a small number of spores to establish in the gut. That makes even trace contamination in a formula used repeatedly across weeks of feeding a potentially serious risk.

    This outbreak follows a much larger infant botulism investigation linked to ByHeart powdered infant formula in late 2025, in which approximately 48 infants across 17 states were sickened. Two formula-linked botulism outbreaks within less than a year has raised urgent questions about manufacturing safety protocols and oversight across both domestic and international production facilities.

    What We Know So Far

    The four confirmed cases involve male infants who fell ill between April and May 2026. They ranged in age from approximately 68 to 153 days old at the time of illness onset, according to reporting from Food Safety Magazine. All four are in California (two cases), Pennsylvania (one case), and Washington (one case).

    Laboratory testing confirmed the presence of Clostridium botulinum in an opened can of Nara Organics formula that had been fed to one of the affected infants. Testing of an unopened can from the same production lot is still underway; results are expected in the coming weeks, per the FDA.

    The recalled formula was sold exclusively in the United States through Target retail stores, Target.com, and Nara.com between July 2025 and June 2026. Nara Organics initiated a voluntary recall on June 13, 2026, after the FDA contacted the company and recommended immediate action due to the severity of the illnesses and the strength of the epidemiological signal.

    Nara Organics’ formula is manufactured in Germany by Milchwerke Mittelelbe GmbH (Elb-Milch), a subsidiary of the Krüger Group. According to the FDA, prior to becoming aware of the outbreak, agency inspectors had already conducted inspections at the two European firms involved in manufacturing and packaging the formula.

    Where the Risk Is Highest

    The formula was distributed nationally, meaning families in every U.S. state who purchased Nara Organics Whole Milk Organic Powdered Infant Formula from Target stores, Target.com, or Nara.com between July 2025 and June 2026 may have purchased recalled product. All lots currently on the market were included in the recall.

    The three specific lots consumed by affected infants are lot codes 709125280E14F2, 709125288E14F2, and 708125174E14F2, according to Nara Organics’ recall notice. However, given that the recall covers all lots, parents should not limit their concern to these lot numbers — any Nara Organics formula purchased during the distribution window should be treated as recalled.

    The Washington State Department of Health has confirmed a case in Thurston County. California has confirmed two cases. Pennsylvania has confirmed one case.

    What Doctors and Public Health Officials Say

    The FDA issued a direct warning in connection with the July 6 update: “Parents and caregivers should stop using Nara Organics Whole Milk Organic Infant Formula immediately,” the agency stated. “If your child is experiencing symptoms after consuming Nara Organics Whole Milk Organic Infant Formula, seek immediate health care.”

    The CDC has stated clearly that botulism can be fatal and that any parent whose infant consumed the recalled formula and is showing symptoms should seek emergency care before contacting health authorities.

    Dr. Wendy Schuchat, who has advised on prior infant botulism investigations, has noted that the rarity of this condition makes rapid recognition by parents and pediatricians critically important. “Infant botulism often starts with what looks like constipation or a tired baby — but it can escalate quickly,” she has said in previous guidance contexts. “Delayed recognition is the most dangerous factor.”

    The IBTPP at the California Department of Public Health is available 24 hours a day, seven days a week, for physician case consultation at 510-231-7600. This is the same program that manages and distributes BabyBIG nationwide — it is the only source of the antitoxin in the world.

    What the Evidence Shows — and What It Does Not

    Laboratory confirmation of Clostridium botulinum in an opened can of the recalled formula fed directly to one of the affected infants provides a strong direct link between the product and the illness. Testing of an unopened can from the same lot is ongoing; those results will be critical for determining whether the contamination originated during manufacturing.

    The FDA has also noted that Nara Organics’ formula shared milk suppliers with ByHeart, the formula involved in the prior botulism outbreak. Specifically, both used milk supplied by Organic West Milk. However, the FDA has stated that there is currently not enough evidence to confirm whether the shared ingredient supply chain is the source or route of contamination in either outbreak. This connection is being actively investigated.

    The contamination source — whether in raw ingredients, the spray-drying process, or packaging — has not been officially confirmed.

    MedicalDaily Evidence Check

    • Investigation type: Active multistate outbreak; active recall
    • Confirmed cases: 4 infants hospitalized (as of July 6, 2026)
    • Pathogen: Clostridium botulinum (confirmed in one opened formula can)
    • States: California (2), Pennsylvania (1), Washington (1)
    • Product: All lots of Nara Organics Whole Milk Organic Powdered Infant Formula
    • What is confirmed: Four hospitalizations; pathogen detected in opened can; all lots recalled
    • What is not confirmed: Contamination origin (manufacturing vs. ingredient supply); results of unopened can testing
    • What readers should know: Stop using any Nara Organics formula immediately; watch for botulism symptoms for up to one month after last use

    Who Faces the Greatest Risk?

    Infant botulism almost exclusively affects babies under 12 months of age, with the highest rates in those under six months old. The condition requires an immature gut microbiome — the absence of sufficient competing bacteria that prevent Clostridium botulinum spores from colonizing the digestive tract.

    Infants at greatest risk include:

    • Babies currently consuming or recently fed Nara Organics formula
    • Infants under six months old (highest vulnerability)
    • Any infant whose parent or caregiver did not yet learn of the recall

    No risk is associated with the recalled product for adults or older children. Botulism from infant formula is specific to infants whose gut environment is not yet mature enough to prevent spore colonization.

    Symptoms and Warning Signs to Watch For

    Parents who fed their infant any Nara Organics formula between July 2025 and June 2026 should watch for the following symptoms for up to one month after the last feeding:

    • Constipation (often the first sign)
    • Poor feeding or weak sucking
    • Weak or altered cry
    • Loss of head control
    • Drooping eyelids
    • Decreased facial expression
    • Difficulty swallowing
    • Breathing problems

    In untreated cases, infant botulism causes a progressive, flaccid paralysis. Respiratory failure can occur and requires mechanical ventilation. Hospitalization typically lasts weeks.

    Seek immediate emergency care if any of these symptoms appear. Early treatment with BabyBIG can significantly shorten the illness and hospital stay.

    What You Can Do Now

    • Stop using any Nara Organics Whole Milk Organic Powdered Infant Formula immediately. Do not feed it to your baby.
    • Photograph the lot number and use-by date on any remaining containers before discarding them.
    • Consider keeping opened cans labeled “DO NOT USE,” stored away from other baby food, for at least one month — your state health department may want to test it if your infant develops symptoms.
    • Discard unopened cans. Customers who purchased from Nara.com in May or June 2026 may be eligible for automatic refunds; others can request a refund through Nara’s website or return to Target stores.
    • Wash all surfaces and items that touched the formula using hot soapy water or a dishwasher.
    • Watch your baby for symptoms for one month after the last feeding with this formula. Symptoms can take several weeks to appear.
    • Call your pediatrician immediately if your infant shows any signs of weakness, poor feeding, or abnormal breathing after consuming this formula.

    Cost and Access: What Patients Should Know

    BabyBIG — botulism immune globulin intravenous (BIG-IV) — is the only FDA-approved treatment for infant botulism caused by toxin types A and B. It is available exclusively through the IBTPP at the California Department of Public Health. Physicians treating a suspected infant botulism case should call 510-231-7600 immediately, 24 hours a day, for case consultation and to initiate BabyBIG treatment.

    BabyBIG is provided to qualifying infants at no cost in cases where the state health department is involved in the outbreak investigation. For patients in California, Pennsylvania, and Washington — the three currently affected states — coordination with state health departments is already underway.

    The recall does not create a formula shortage. Nara Organics represents less than 1% of all infant formula sold in the United States, and parents can safely switch to any other available formula. Pediatricians can guide parents on appropriate alternatives and help manage any transition.

    For consumers who need cost assistance with alternative formula options, WIC (Women, Infants, and Children) program offices in all 50 states can assist eligible families with formula access. Find your local WIC office at www.fns.usda.gov/wic.

    What Happens Next

    Laboratory testing of an unopened can from the affected lot is expected to yield results in the coming weeks. Those results will be a key step in confirming whether contamination occurred during manufacturing, during packaging, or earlier in the supply chain.

    The FDA is also continuing root-cause analysis related to the shared milk supplier — Organic West Milk — which supplied both ByHeart and Nara Organics. Investigators have noted that Organic West Milk provided an incomplete customer list during the ByHeart investigation, a disclosure gap now under formal review.

    Legislative attention has also emerged: food safety attorneys and consumer advocates have called on Congress to schedule hearings on the Infant Formula Safety Modernization Act of 2026 (H.R. 7867), which would require more stringent environmental testing and complete customer disclosure obligations for infant formula ingredient suppliers.

    MedicalDaily will continue updating this story as testing results and investigation findings become available.

    The Bottom Line

    Four infants — all boys under five months old — have been hospitalized with confirmed botulism linked to a single recalled formula brand. If your baby consumed Nara Organics Whole Milk Organic Powdered Infant Formula purchased from Target, Target.com, or Nara.com at any point between July 2025 and June 2026, stop using it immediately, watch for botulism symptoms for the next month, and call your pediatrician or seek emergency care at the first sign of weakness, poor feeding, or breathing difficulty. This investigation is ongoing.

    Source link

  • U.S. Airport Ebola Screening Remains Active Through July 21: What Returning Travelers Need to Know

    U.S. Airport Ebola Screening Remains Active Through July 21: What Returning Travelers Need to Know

    Enhanced Ebola screening is currently active at three major U.S. international airports, and entry restrictions for travelers from the Democratic Republic of the Congo, Uganda, and South Sudan remain in effect through approximately July 21, 2026. The measures were put in place in response to a growing outbreak of Bundibugyo virus disease — a rare and potentially fatal strain of Ebola for which no approved vaccine or specific treatment exists.

    Travelers who have recently returned from those regions, or who plan to travel there, need to understand what these measures require and what symptoms demand immediate medical attention.

    Why This Matters

    The Bundibugyo strain of Ebola is not the same as the Zaire strain responsible for West Africa’s 2014–2016 epidemic. The FDA-approved Ebola vaccine that provided protection in those prior outbreaks is not considered effective against the Bundibugyo virus. There are no approved countermeasures specific to this strain, which means containment relies on surveillance, contact tracing, isolation, and border screening.

    Case fatality rates for Bundibugyo virus disease in prior outbreaks have ranged from approximately 25% to 50%, according to the CDC — lower than Zaire Ebola but still highly serious. Patients experience fever, vomiting, severe weakness, and in some cases bleeding. Without a vaccine or treatment option, early identification of cases among arriving travelers is critical to preventing domestic spread.

    The World Health Organization has declared this outbreak a Public Health Emergency of International Concern — its highest alert designation.

    What We Know So Far

    The DRC’s Ministry of Health confirmed the Bundibugyo outbreak on May 15, 2026, after laboratory analysis identified Bundibugyo virus in samples from clusters of severe illness and deaths in Ituri Province. The affected health zones — Mongbwalu and Rwampara — are in northeastern DRC near the Ugandan border.

    By mid-June 2026, the DRC had reported 837 confirmed cases and 196 confirmed deaths. Uganda confirmed cases linked to travelers from DRC. South Sudan, which borders both countries, has not confirmed any cases but is included in U.S. entry restrictions due to the geographic risk.

    The U.S. response has been layered:

    As of the most recent CDC update, one American citizen who worked in DRC tested positive for Ebola but has since fully recovered and was released from care. High-risk contacts completed 21-day monitoring without developing symptoms. The CDC assesses the risk to the general U.S. public as low. No cases have been acquired domestically.

    Which Airports Are Conducting Screening

    The CDC and U.S. Customs and Border Protection (CBP) are conducting enhanced Ebola screening at three designated airports for travelers arriving from DRC, Uganda, or South Sudan:

    • Washington Dulles International Airport (IAD) — for flights departing affected countries after May 21, 2026
    • Hartsfield-Jackson Atlanta International Airport (ATL) — for flights after May 22, 2026
    • George Bush Intercontinental Airport, Houston (IAH) — for flights after May 26, 2026

    U.S. citizens and nationals who have been in the affected countries are permitted to return but must enter through one of these designated airports and undergo enhanced public health screening, which may include a health interview, temperature check, and review of symptoms. Travelers without symptoms will receive monitoring instructions and may continue to their final destination.

    According to the U.S. Embassy in DRC, travelers should be prepared for possible flight changes or cancellations when routing through these airports.

    Where the Risk Is Highest

    The active outbreak is concentrated in Ituri Province in northeastern DRC, particularly the Mongbwalu and Rwampara health zones. The CDC notes that the affected areas experience insecurity, population displacement, mining-related movement, and frequent cross-border traffic — all factors that increase transmission risk and complicate outbreak containment.

    In the United States, travelers and healthcare workers who have recently returned from DRC, Uganda, or South Sudan face the primary risk. International humanitarian workers, aid and medical personnel, journalists, researchers, and missionaries are the groups with the highest likelihood of having been in outbreak zones.

    Healthcare facilities in Atlanta, Houston, and the Washington D.C. metropolitan area should maintain heightened awareness given their proximity to the designated screening airports. Emergency departments and infectious disease units in these cities are most likely to encounter a returning traveler who develops symptoms during the 21-day monitoring period.

    What Doctors and Experts Say

    The CDC’s Health Alert Network advisory (HAN 00530) issued May 19, 2026, emphasized that “the risk of spread to the United States is considered low at this time” but called on clinicians to remain vigilant. The agency stated it is working through its country offices and international partners to support disease tracking, contact tracing, laboratory testing, and border health screening.

    The CDC noted a specific challenge with this outbreak: the FDA-approved vaccine (Ervebo) is effective against Zaire ebolavirus — the species responsible for major past outbreaks — but is not considered effective against Bundibugyo virus. The absence of an approved countermeasure for this strain makes infection control and early case detection especially critical.

    WHO Director-General Tedros Adhanom Ghebreyesus, in public statements cited across multiple outlets covering the outbreak’s early weeks, acknowledged that the delay in detecting the initial cluster meant response teams were “playing catch-up with a very fast-moving epidemic.” Contact tracing, treatment center establishment, and infection control measures have been scaled up since.

    For healthcare providers seeing patients who have returned from affected regions, the CDC recommends immediately placing potentially symptomatic patients under appropriate infection control precautions and contacting local or state public health departments for guidance on testing and isolation.

    What the Evidence Shows and What It Does Not

    The Bundibugyo virus has caused only two prior recorded outbreaks — Uganda in 2007 and DRC in 2012 — making it less well-studied than Zaire ebolavirus. Prior outbreaks had case fatality rates of approximately 25% to 50%, but that range reflects small sample sizes and variable outbreak conditions.

    Airport screening can identify travelers who are symptomatic at the time of arrival but cannot detect those who are infected but not yet showing symptoms. As the CDC states: “Public health entry screening cannot identify travelers who are infected but not yet showing symptoms.” The incubation period for Ebola is 2 to 21 days. Screening is therefore one component of a multilayered public health response, not a complete safeguard.

    The 21-day post-departure monitoring requirement for returning travelers exists precisely because of this gap.

    Who Faces the Greatest Risk?

    Based on current epidemiological data and CDC guidance, the highest-risk individuals in the United States are:

    • People who have traveled to or from Ituri Province, DRC, within the past 21 days
    • Humanitarian aid workers, healthcare volunteers, and missionary workers returning from DRC or Uganda
    • People who had direct contact with the blood or bodily fluids of a person confirmed or suspected to have Bundibugyo virus disease
    • Healthcare workers who treated or evaluated patients with suspected BVD without full personal protective equipment
    • Individuals who attended funerals or burial ceremonies in affected areas, where transmission risk is historically elevated

    The CDC’s Level 2 Travel Health Notice recommends avoiding nonessential travel to the specific affected provinces in DRC (Ituri, Nord-Kivu, and Sud-Kivu).

    Symptoms and Warning Signs to Watch For

    Anyone who has been in DRC, Uganda, or South Sudan within the past 21 days should monitor themselves carefully for the following symptoms, which may appear between 2 and 21 days after exposure:

    • Sudden onset of fever (often above 101.5°F / 38.6°C)
    • Severe headache
    • Muscle pain and weakness
    • Fatigue
    • Vomiting and diarrhea
    • Stomach pain
    • Unexplained bleeding or bruising (typically a later sign)

    The development of any of these symptoms in a person who has recently returned from an affected region requires immediate action. Do not travel to a hospital or clinic without calling first. Contact your local health department or call 911 and tell the dispatcher about your recent travel and symptoms so that appropriate isolation procedures can be prepared before you arrive.

    What You Can Do Now

    • If you recently returned from DRC, Uganda, or South Sudan, follow your state or local health department’s monitoring instructions for 21 days after your departure date from those countries.
    • Monitor your temperature daily and record any symptoms during the 21-day window.
    • Avoid international and domestic travel during your monitoring period, per CDC recommendations.
    • If you develop any symptoms, do not go directly to a hospital. Call your local health department and inform them of your travel history before seeking care.
    • Register with the Smart Traveler Enrollment Program (STEP) if you are a U.S. citizen in DRC, Uganda, or South Sudan, so the nearest embassy can provide updates and assistance.
    • Healthcare providers who evaluate a returning traveler with fever or other compatible symptoms should immediately implement infection control measures and notify their state health department and the CDC Emergency Operations Center at 770-488-7100.

    Cost and Access: What Patients Should Know

    If a returning traveler is identified as a potential Ebola case, isolation and evaluation will be coordinated by public health authorities. The CDC maintains a network of federal medical stations and Regional Ebola and Special Pathogen Treatment Centers (RESPTCs) capable of safely managing patients with highly infectious diseases.

    For general travelers concerned about health coverage abroad, the U.S. Department of State recommends purchasing travel insurance that includes medical evacuation coverage before traveling to high-risk regions.

    What Happens Next

    The current U.S. entry restriction order expires around July 21, 2026, but may be extended if the outbreak continues to grow. The CDC will assess the epidemiological situation and issue updates as warranted.

    WHO and international partners are working to scale up outbreak response in DRC and Uganda, including contact tracing, treatment access, and community engagement in affected areas. Given that no approved vaccine or specific treatment exists for Bundibugyo virus, containment measures remain the primary line of defense.

    MedicalDaily will follow CDC updates and the WHO outbreak situation report as they are published.

    The Bottom Line

    Ebola airport screening is active at Dulles, Atlanta, and Houston through at least July 21, 2026. The Bundibugyo strain currently affecting DRC and Uganda has no approved vaccine or treatment, and the outbreak has now surpassed 800 confirmed cases with nearly 200 deaths. The CDC assesses the risk to the general U.S. public as low.

    But low risk does not mean no risk. Travelers who have been in affected regions must monitor themselves for symptoms for 21 full days after departure and must contact health authorities — not walk into an emergency room — if symptoms develop. Following official CDC and state health department guidance is the single most important step returning travelers can take.

    Source link

  • Washington, D.C., Was Just Hit with a Purple Air Quality Alert, the Second-Highest Level on the Air Quality Index

    Washington, D.C., Was Just Hit with a Purple Air Quality Alert, the Second-Highest Level on the Air Quality Index

    Washington, D.C., residents and the millions of visitors who attended America 250 celebrations on the National Mall have been advised to limit outdoor activity following a rare “Purple” air quality alert — the second-worst category on the federal Air Quality Index — triggered by a convergence of record-breaking heat and smoke from the largest fireworks display in American history.

    The Metropolitan Washington Council of Governments issued the purple alert covering Washington, D.C., and parts of northern Virginia. Purple on the EPA’s Air Quality Index represents “Very Unhealthy” conditions — a level at which the EPA recommends that everyone, including healthy adults, reduce prolonged or heavy outdoor exertion.

    The heat wave stretched from Wednesday through Saturday, and Washington D.C. hit 102°F on July 3, breaking a record set in 1872. On July 4, the capital reached 101°F or higher — the hottest July 4 in D.C.’s recorded history. The combination of that heat wave with a 40-minute, multi-site fireworks display that launched hundreds of thousands of shells produced post-display particulate matter concentrations that CNN confirmed briefly ranked Washington among the worst air quality of any major city in the world.

    Why This Matters

    Most Americans are familiar with air quality alerts for “sensitive groups” — adults with asthma, heart disease, or COPD. A Purple alert is categorically different. At this level, the EPA’s guidance extends to the general population: everyone should avoid prolonged or heavy outdoor exertion, not just those with pre-existing conditions.

    The biological reason that heat and air pollution compound each other is specific. Heat causes people to breathe more deeply and rapidly — increasing the volume of air (and any particulate matter in it) inhaled per minute. Simultaneously, heat stress places additional burden on the cardiovascular system. Inhaling elevated particulate matter during cardiovascular stress creates a compound physiological challenge that healthy adults can normally tolerate but that at purple AQI levels carries documented risks.

    What We Know So Far

    The EPA’s AirNow system tracks fine particulate matter (PM2.5) at monitoring stations across the D.C. metro. Following the July 4 fireworks display:

    • D.C. July 4 temperature: 101°F or higher — the hottest July 4 in D.C.’s recorded history
    • AQI level: Purple — “Very Unhealthy” — the second-highest AQI category after Maroon (“Hazardous”)
    • PM2.5 source: Primarily fireworks smoke from the National Mall and nine additional launch sites
    • Alert area: Washington, D.C., and parts of northern Virginia
    • The AQMD in Southern California had separately issued a “Hazardous” (Maroon) air quality advisory for July 4–5 nationally, confirming the pattern
    • D.C.’s post-fireworks conditions briefly registered among the highest air pollution readings of any major global city

    Where the Risk Is Highest

    The risk is highest in:

    • Neighborhoods downwind of the National Mall and the nine additional fireworks launch sites used for the record display
    • Indoor spaces without air filtration — where smoke particulates can infiltrate through HVAC systems
    • People who remained outdoors after the fireworks ended, when PM2.5 levels were at their peak but the crowd was still dispersing

    The alert covered both D.C. proper and northern Virginia — a corridor of 4 million-plus residents.

    What the EPA Says and Who Faces the Greatest Risk

    At Purple (“Very Unhealthy”) AQI levels, the EPA’s action guidance is:

    • Sensitive groups (people with heart or lung disease, older adults, children, people with diabetes): Avoid all physical activity outdoors
    • Everyone else: Avoid prolonged or heavy outdoor exertion; consider moving activities indoors or rescheduling

    People at the highest risk from the D.C. purple alert:

    • Adults with asthma, COPD, or heart disease
    • Older adults (65+) who attended National Mall events and spent extended time outdoors
    • Children who attended events and are still outdoors
    • People who ran, cycled, or engaged in heavy exertion outdoors during or after the alert period
    • Anyone with diabetes — air pollution independently worsens glycemic control

    Symptoms and Warning Signs to Watch For

    Anyone who spent extended time outdoors during the alert period and experiences the following should contact their physician or seek urgent care:

    • Unusual shortness of breath
    • Chest tightness or discomfort
    • Worsening cough or wheezing
    • Headache, dizziness, or unusual fatigue following outdoor time
    • Worsening asthma or COPD symptoms despite rescue inhaler use

    What You Can Do Now

    • Check current D.C. area air quality at AirNow.gov by entering your zip code. If the AQI remains elevated, limit outdoor activity.
    • Run HVAC on recirculation rather than fresh-air intake to avoid pulling outdoor particulates indoors.
    • Use HEPA air purifiers indoors if available — particularly in bedrooms where nighttime air quality matters for recovery.
    • If you have asthma or COPD, review your action plan with your physician if symptoms have worsened following the alert period.
    • Do not exercise outdoors while the AQI remains in the orange, red, or purple range for your specific neighborhood.
    • If you attended National Mall events and feel unwell, contact your physician, particularly if you have cardiovascular or respiratory conditions.

    Cost and Access: What Patients Should Know

    AirNow.gov provides real-time, zip-code-level air quality data at no cost. The FEMA Wireless Emergency Alert system also broadcasts air quality warnings to mobile phones in affected areas.

    For patients experiencing air quality-related asthma exacerbation who do not have insurance, federally qualified health centers in D.C. and northern Virginia provide urgent care services on a sliding-fee basis. For severe respiratory emergencies, call 911.

    What Happens Next

    The D.C. metro air quality is expected to improve as the fireworks smoke disperses over 48 to 72 hours and as weather systems provide atmospheric mixing. The DOEE (District of Columbia Department of Energy and Environment) updates D.C. air quality data in real time.

    MedicalDaily will report on any prolonged air quality advisories or new health guidance from the D.C. health department related to the post-fireworks pollution event.

    The Bottom Line

    Washington, D.C.’s “Purple” air quality alert — triggered by record heat and the nation’s largest fireworks display — marks one of the most significant post-fireworks air pollution events the city has experienced. At this AQI level, the EPA’s recommendation extends to healthy adults, not just sensitive groups. If you were in the D.C. metro on July 4–5, limit outdoor activity while the AQI remains elevated and watch for respiratory or cardiovascular symptoms.

    Source link

  • Michigan Has More Than 300 Cyclospora Cases and No Food Source Has Been Found

    Michigan Has More Than 300 Cyclospora Cases and No Food Source Has Been Found

    More than 300 people in southeast Michigan have been diagnosed with Cyclosporiasis — a parasitic intestinal illness — since June 22, 2026. The count was 170 on July 1 and jumped to more than 300 by July 3, an increase of 130 cases in 48 hours. Health officials have called it a “large and growing outbreak,” and no food source has yet been identified.

    The Michigan Department of Health and Human Services confirmed the outbreak in Monroe, Lenawee, Washtenaw, Wayne, Livingston, Shiawassee, and Jackson counties — with an additional 24 cases across 11 other Michigan counties, including the city of Detroit. The typical annual count for all of Michigan is around 50 cases. This outbreak has already produced six times that number.

    What makes this especially frustrating for patients and clinicians: the standard stool test used to diagnose acute diarrhea does not detect Cyclospora.

    Why This Matters

    When a patient presents to an urgent care clinic, emergency room, or primary care physician with acute diarrhea, the reflex diagnostic order is typically a “routine stool culture” — a test that screens for common bacterial pathogens including Salmonella, Campylobacter, Shigella, and E. coli.

    Cyclospora cayetanensis, the microscopic parasite that causes Cyclosporiasis, is not detected by a routine stool culture. Identifying it requires a specific laboratory request: a modified acid-fast stain or a Cyclospora-specific PCR. Most clinicians treating acute diarrheal illness in Michigan — or anywhere — do not automatically order these tests.

    The result: patients with Cyclospora may receive a “negative stool test” result, be told their illness is likely viral, and go weeks without the correct diagnosis and effective antibiotic treatment. Untreated, Cyclosporiasis can last weeks to months, with symptoms that repeatedly relapse.

    What We Know So Far

    From the Michigan Department of Health and Human Services (MDHHS) and Click on Detroit / NBC News:

    • Confirmed cases as of July 1: More than 170 in 7 southeast Michigan counties
    • Confirmed cases as of July 3: More than 300 (up from 170 in 48 hours)
    • Additional cases: 24 more in 11 other Michigan counties, including Detroit
    • Age range: 8 to 84 years; median age 41
    • Typical annual Michigan total: 50 cases per year
    • Current count: Approximately 6 times the typical annual total
    • Food source: Not yet identified; investigation ongoing by MDHHS and MDARD
    • National context: Nationally, the CDC has confirmed 145 Cyclosporiasis cases in 17 states as of June 16, 2026 — Michigan cases are not included in this national count

    “Outbreaks of cyclosporiasis have been occurring across the United States and now here in Michigan,” said Dr. Natasha Bagdasarian, Chief Medical Executive at MDHHS. “Based on the unusual number of cases we have identified in a little over a week, we anticipate additional cases of illness being reported.”

    Where the Risk Is Highest

    The seven-county cluster in southeast Michigan defines the primary outbreak zone:

    • Monroe County: 67+ confirmed cases as of July 1 — the county with the highest confirmed count
    • Wayne County: Includes Detroit and is confirmed in the outbreak cluster
    • Lenawee, Washtenaw, Livingston, Shiawassee, and Jackson Counties: All confirmed in the outbreak

    The concentration of cases in this specific geographic area suggests a common exposure source — likely a food product distributed in this region during the incubation window before June 22. The investigation by MDHHS and the Michigan Department of Agriculture and Rural Development (MDARD) is focused on identifying that product.

    What the MDHHS and Local Health Officials Say

    “We currently have 67 cases in Monroe County. We are currently investigating the source. This is caused by an intestinal parasite. It’s from contaminated food,” said Lindsay Patrick with the Monroe County Health Department in a statement to WXYZ Detroit.

    Jennifer Bonsky, Director of the Human Food Division at MDARD, stated: “MDARD is committed to ensuring food safety across the state and is working in partnership with local health departments to identify the source of the outbreak and keep consumers safe.”

    Clinicians at Michigan hospitals and urgent care clinics are being specifically urged to consider Cyclosporiasis in patients presenting with acute gastrointestinal illness — and to order the correct diagnostic test.

    What the Evidence Shows — and What It Does Not

    MedicalDaily Evidence Check

    • Data source: Michigan Department of Health and Human Services; Monroe County Health Department; NBC News; Click on Detroit
    • Cases as of July 3: 300+ in 7 southeast Michigan counties; investigation ongoing
    • Food source: Not yet identified; no recall issued
    • What the data show: A large, rapidly growing parasitic outbreak concentrated in a specific geographic area in southeast Michigan — consistent with a contaminated food product with regional distribution
    • What is not yet known: The specific food, supplier, or contamination source
    • Critical diagnostic limitation: Standard stool cultures do not detect Cyclospora; a specific modified acid-fast stain or PCR test is required

    Who Faces the Greatest Risk?

    Any person who consumed fresh produce in the affected Michigan counties in late May or June 2026 is potentially exposed. The highest clinical risk for prolonged illness includes:

    • Immunocompromised individuals, for whom Cyclosporiasis can last significantly longer and require more intensive treatment
    • Older adults
    • Individuals who have already experienced weeks of diarrhea with no diagnosis — who may be infected and untreated

    Symptoms and Warning Signs to Watch For

    Cyclosporiasis symptoms include:

    • Frequent, sometimes explosive watery diarrhea — the hallmark symptom
    • Stomach cramping and bloating
    • Nausea and vomiting
    • Loss of appetite
    • Fatigue and muscle aches
    • Low-grade fever

    The most diagnostically important feature: Cyclosporiasis often waxes and wanes— symptoms improve for a few days, then return. A patient who received a negative standard stool test and was told their illness is viral may actually have untreated Cyclospora if their symptoms have persisted or recurred.

    What You Can Do Now

    • If you live in Monroe, Lenawee, Washtenaw, Wayne, Livingston, Shiawassee, or Jackson counties and have had prolonged, recurring diarrhea since late May or June, contact your healthcare provider.
    • Tell your physician specifically: “I want to be tested for Cyclospora. I need a modified acid-fast stain or a Cyclospora-specific PCR, not just a routine stool culture.”
    • Do not assume a negative routine stool test rules out Cyclospora. It does not.
    • If you have already had a “negative stool test” but symptoms have persisted or returned, go back to your provider and ask specifically for Cyclospora testing.
    • Effective treatment is available: The antibiotic combination trimethoprim-sulfamethoxazole (Bactrim) is highly effective for Cyclosporiasis. Without a correct diagnosis, you will not receive it.

    Cost and Access: What Patients Should Know

    Cyclospora-specific testing must be specifically requested by a physician. The test is covered by most insurance plans; generic trimethoprim-sulfamethoxazole (Bactrim) is available at most pharmacies for under $10 with a GoodRx discount.

    Patients without primary care access can contact their county health department or a community health center. Monroe County residents with questions can contact the Monroe County Health Department directly.

    What Happens Next

    MDHHS and MDARD are continuing the investigation to identify the contaminated food source. The case count, already at more than 300 and still growing, is expected to rise further as health officials expand testing and surveillance. MedicalDaily will report immediately when a food source is identified or a recall is issued.

    The Bottom Line

    More than 300 people in southeast Michigan have been diagnosed with a parasitic intestinal illness in under two weeks — six times the state’s typical annual total. No food source has been found. And the most common diagnostic test ordered for acute diarrhea does not detect this parasite. If you have had prolonged or recurring watery diarrhea in the affected counties since late May, you need a Cyclospora-specific test — not a routine stool culture. Ask for it by name.

    Source link

  • The CDC Is Investigating Multiple Cyclospora Outbreaks, and This Parasite Is Particularly Hard to Trace

    The CDC Is Investigating Multiple Cyclospora Outbreaks, and This Parasite Is Particularly Hard to Trace

    A parasitic illness is spreading across the United States this summer, and after weeks of investigation, federal health officials still cannot identify the specific food responsible for making people sick. The frustrating lack of a recall announcement is not a failure of urgency — it is a reflection of how uniquely difficult this particular parasite is to track.

    The Centers for Disease Control and Prevention has confirmed 145 domestically acquired cases of Cyclospora cayetanensis infection in 17 states, with illness onset dates from May 1 through June 7, 2026. Three people have been hospitalized. No deaths have been reported. But the case count is almost certainly a substantial undercount, and the absence of a specific food recall does not mean the outbreak is over.

    Why This Matters

    Cyclospora is not a pathogen that clinicians or patients typically think about first when gastrointestinal illness strikes. It requires a specific test that most clinical labs do not routinely run. It has an incubation period of 1 to 2 weeks — long enough that by the time patients seek care, they may not clearly remember what they ate that could have been contaminated. And it contaminates at the farm or irrigation level, not during processing, making the traceback chain longer and harder to follow.

    The result is predictable: most infected people are never diagnosed, the food source takes weeks or months to identify, and even after the source is found, the implicated product has often already moved through the supply chain and been consumed. Summer is the peak season for Cyclospora in the United States, meaning the number of cases is expected to grow before it peaks.

    What We Know So Far

    From CDC’s Cyclospora surveillance data current as of June 16, 2026, and FDA outbreak investigation table:

    • 145 confirmed U.S.-acquired cases in 17 states
    • 20 hospitalizations confirmed among cases with information available
    • No deaths reported
    • Illness onset dates: May 1 through June 7, 2026; median onset May 19
    • Median patient age: 43 years; 62 percent female
    • 45 travel-associated cases confirmed separately (patients ill while outside the United States)
    • Only 45 of the 145 domestic cases involve people who reported recent international travel — confirming a domestic food source is responsible
    • Michigan: More than 150 cases in 7 counties reported by state health officials — a count not yet included in the CDC’s 17-state national total
    • New York leads confirmed state counts at approximately 80 cases; Texas and Illinois each report up to 30
    • Food source: Not yet identified. No recall has been issued.

    Where the Risk Is Highest

    Cyclospora illness has been reported in 17 states, with no single geographic cluster that would suggest a local exposure. That distribution is consistent with contaminated produce distributed nationally — a pattern seen in every major Cyclospora outbreak in the United States since the 1990s.

    Prior outbreaks have repeatedly linked to fresh produce from Mexico and Central America, particularly cilantro, basil, fresh leafy greens, arugula, and bagged salad kits. The 2018 Cyclospora outbreak sickened more than 511 people across the Midwest and was linked to a fast-food chain’s salad mix. In 2020, fresh cilantro from a Texas distributor sourcing from Mexico was implicated in an Alabama cluster.

    Until a specific product is identified in this investigation, no targeted recall can be issued — and public health guidance must remain general: exercise caution with fresh herbs and leafy greens, particularly those imported from high-risk regions during the summer months.

    The Three Reasons Cyclospora Is So Difficult to Trace

    1. The incubation period makes exposure memory unreliable. Cyclospora has a 1-to-2-week incubation period between exposure and symptom onset. By the time a person seeks medical care, they typically cannot accurately recall every meal from the past 10 to 14 days. This makes dietary recall interviews — the primary tool for identifying contaminated foods — less reliable than in outbreaks caused by faster-acting pathogens like Salmonella, where the exposure meal is typically more recent.

    2. The parasite is not detected by standard stool testing. Standard clinical stool cultures do not include Cyclospora testing. A physician must specifically order a modified acid-fast stain or a direct fluorescence assay for Cyclospora, or a PCR-based test in clinical labs that offer it. Most primary care physicians and emergency physicians seeing a patient with prolonged diarrhea in the summer do not reflexively order Cyclospora testing — because most GI illness is caused by something else. This means the majority of Cyclospora cases go undiagnosed, and those that are diagnosed often experience significant delays.

    3. The contamination occurs at the farm or irrigation level, not during processing. Unlike foodborne bacterial contamination that can often be traced to a specific processing step or facility, Cyclospora contamination of produce typically occurs when irrigation water contaminated with human feces contacts crops in the field. This farm-level contamination makes traceback investigations far more complex — and means that the same contaminated irrigation source may affect multiple products from the same farm, complicating identification of a single “suspect” item.

    What Doctors and Experts Say

    The CDC’s clinical guidance for Cyclospora explicitly notes that health care providers should specifically request Cyclospora testing when they see patients with prolonged or recurring watery diarrhea, particularly from May through August.

    “Cyclospora is one of those infections that really tests physicians’ diagnostic instincts,” infectious disease specialists have noted in public health communications. The infection is treatable — a full course of trimethoprim-sulfamethoxazole (Bactrim) typically resolves illness — but the window in which to catch it relies on knowing to order the right test.

    What the Evidence Shows — and What It Does Not

    The CDC has explicitly stated there is no evidence of a single, unified nationwide Cyclospora outbreak. The 145 confirmed cases reflect a surveillance count of domestically acquired infections across the United States during the summer peak season, with multiple clusters currently under separate traceback investigation.

    MedicalDaily Evidence Check

    • Investigation status: Active multistate investigation, multiple clusters
    • Confirmed U.S. cases: 145 in 17 states (as of June 16, 2026); true total likely substantially higher
    • Food source: Not yet identified; no recall issued
    • What the data show: Domestic food exposure is confirmed as the primary driver (only 45 of 145 cases involve recent international travel)
    • What remains unknown: Specific implicated product or supplier
    • What readers should know: Cyclospora requires a specific lab test not included in standard stool cultures; prolonged diarrhea lasting more than a week warrants evaluation and explicit testing for this parasite

    Who Faces the Greatest Risk?

    Anyone who has consumed fresh produce — particularly leafy greens, fresh herbs like cilantro and basil, or bagged salad mixes — since May 1, 2026, could potentially have been exposed. However, certain groups are more likely to develop prolonged or serious illness:

    • Immunocompromised individuals, including organ transplant recipients, people with HIV, and cancer patients on chemotherapy, who may develop severe or prolonged disease
    • Adults who consume large quantities of fresh herbs and leafy greens regularly
    • Older adults, in whom infection can last longer and cause more significant weight loss and dehydration

    Symptoms and Warning Signs to Watch For

    The hallmark symptom of Cyclospora infection is:

    • Frequent, watery, sometimes explosive diarrhea that waxes and wanes over days to weeks
    • Cramping and bloating
    • Nausea and decreased appetite
    • Fatigue and muscle aches
    • Low-grade fever

    Without treatment, symptoms can last weeks and frequently return in cycles. If you have had persistent, recurring watery diarrhea lasting more than a week — especially if standard tests have come back negative — ask your doctor specifically about Cyclospora testing. Standard stool cultures do not detect this parasite unless specifically requested.

    What You Can Do Now

    • If you have prolonged or recurring diarrhea, see a clinician and specifically ask about Cyclospora testing. Use the words: “I want to be tested for Cyclospora, not just a standard stool culture.”
    • Do not self-treat with over-the-counter antidiarrheal medications as a substitute for diagnosis. If the cause is Cyclospora, antibiotic treatment is needed.
    • Wash all fresh produce thoroughly under running water before eating. While washing does not kill Cyclospora (the parasite resists standard disinfection), it reduces other surface contamination.
    • Exercise caution with fresh herbs — particularly cilantro, basil, and arugula purchased in bulk or from salad bars — until a food source is identified.
    • If you are immunocompromised, discuss your risk level with your physician.

    Cost and Access: What Patients Should Know

    Testing for Cyclospora requires a specific physician order for a modified acid-fast stain or PCR Cyclospora test. Treatment with generic trimethoprim-sulfamethoxazole (Bactrim) is inexpensive — often under $10 with a GoodRx discount at most pharmacies.

    For patients without a primary care provider, urgent care clinics and community health centers can order Cyclospora-specific stool testing. People experiencing severe dehydration, blood in the stool, or inability to keep fluids down should seek emergency care.

    What Happens Next

    The FDA and CDC are continuing traceback investigations into multiple clusters. New case data will be posted at CDC’s Cyclospora surveillance page as the investigation progresses. When a food source is identified, the FDA will issue a public advisory and, if a specific product is implicated, initiate or request a recall.

    MedicalDaily will report immediately when a food source is confirmed or a recall is issued.

    The Bottom Line

    The absence of a Cyclospora food recall is not reassurance — it is a reflection of how difficult this parasite is to trace. The investigation is active, the case count is almost certainly higher than reported, and summer is the peak exposure period. If you have had prolonged, waxing-and-waning diarrhea since May and standard tests have not identified a cause, ask specifically for Cyclospora testing. Treatment is effective once the correct diagnosis is made.

    Source link

  • Infant Formula Makers Were Required to Tell the FDA When Babies Died — Records Show They Never Did

    Infant Formula Makers Were Required to Tell the FDA When Babies Died — Records Show They Never Did

    When makers of infant formula learn that babies have become seriously ill or died after using their products, federal regulations require them to notify the FDA. But in a major investigative finding published July 2, 2026, KFF Health News revealed that the FDA has no record of a single such notification from any formula manufacturer going back more than 26 years.

    That gap in the federal safety record is not because premature infants haven’t died. According to a KFF Health News analysis of federal data, approximately 2,300 newborns died from necrotizing enterocolitis (NEC) in the United States between 2017 and 2023 — roughly one per day. A wave of more than 1,700 lawsuits has alleged that formula made by Abbott (Similac) and Mead Johnson (Enfamil) caused or contributed to these deaths by triggering NEC in premature infants, and that manufacturers knew about the elevated risk without adequately warning parents or physicians.

    Why This Matters

    Federal regulations give infant formula manufacturers substantial discretion in deciding whether and when to notify the FDA that a product may have contributed to a serious adverse event. According to KFF Health News’s investigation, that discretion has translated to zero notifications — even as hundreds of lawsuits proceeded through the courts and testimony from company executives confirmed that internal records of adverse events existed and were investigated internally.

    The practical consequence is significant: parents harmed by formula have been fighting Abbott and Mead Johnson in court, with no government notification system creating an independent safety record. Families who lose a premature infant to NEC are not informed that other families have reported the same outcome to the manufacturer. And the FDA — which does not pre-approve infant formula before it reaches the market — has had no formal mechanism to detect a pattern of harm tied to specific products.

    What We Know So Far

    From KFF Health News’s FOIA investigation published July 2, 2026, and court records cited in the report:

    • Under the Freedom of Information Act, KFF Health News asked the FDA for all notifications from formula manufacturers since January 1, 2020. The agency’s Human Foods Program responded: “did not receive any.”
    • KFF Health News extended the request to January 1, 2000. The FDA responded: “After a diligent search of our files, we did not locate any responsive records.”
    • John Wallingford, a paid expert witness for Abbott, testified in Missouri court in October 2024 that “Abbott had never reported a single death under any regulation for preterm infant formula.”
    • Courtney Colombo, who identified herself in a March 2024 deposition as Abbott’s director of postmarketing medical safety and surveillance, testified she knew of no instance in which Abbott had reported to any regulatory authority anywhere in the world that one of its preterm infant formulas was possibly related to a NEC death.
    • An Abbott internal document from 2010, displayed in deposition video clips obtained by KFF Health News, stated that NEC “is the most severe GI complication of prematurity and the use of bovine milk-based fortifiers and formulas are believed to be the primary risk factor.”
    • A Mead Johnson marketing slide deck from 2020 — later used in trial — outlined a plan for “Branding NICU Babies,” a strategy to capture preterm infant feeding contracts through hospital relationships.
    • As of late January 2026, approximately 1,760 NEC lawsuits were pending against Abbott alone.
    • About 2,300 newborns died of NEC in the U.S. from 2017 through 2023, the equivalent of nearly one per day. The database does not attribute causation.

    Where the System Fails Families

    The regulatory framework governing infant formula reporting gives manufacturers the authority to determine whether adverse events — including deaths — meet the threshold requiring FDA notification. Unlike pharmaceutical drugs, which are subject to rigorous post-market surveillance and mandatory serious adverse event reporting with specific timelines, infant formula operates under a framework in which reporting is largely at the manufacturer’s discretion.

    The FDA does not approve infant formula products before they reach market. It does not license formula labeling for safety claims. And, according to the KFF Health News investigation, its Human Foods Program received zero death notifications from formula makers across a 26-year window — even as internal company documents confirmed the companies were tracking NEC-related complaints internally.

    This creates a structural gap: a manufacturer can investigate an adverse event internally, close the file internally, and the FDA may never receive a notification that allows it to identify a pattern of harm.

    What the Companies and Agencies Say

    Abbott spokesperson Scott Stoffel stated in November that “Abbott complies with all applicable FDA regulations on adverse event reporting, including by keeping detailed records of every single complaint/adverse event report Abbott receives and investigating NEC complaints.”

    The FDA stated in a 2024 joint statement with the CDC and NIH that there is “no conclusive evidence that preterm infant formula causes NEC.” Abbott’s chief executive has publicly said that claims linking preterm formula to NEC are “without merit or scientific support.”

    However, courts have repeatedly found in favor of families suing Abbott and Mead Johnson. A Chicago jury awarded $53 million to four families in April 2026, and a separate Chicago verdict in the same month awarded an additional $70 million. A Missouri appeals court upheld a $495 million verdict against Abbott. As of June 2026, approximately 798 federal NEC cases remain pending in multidistrict litigation in the Northern District of Illinois, with hundreds more in state courts.

    What the Evidence Shows — and What It Does Not

    The scientific debate over whether bovine (cow’s milk-based) formula causes NEC in premature infants versus the absence of human milk increasing NEC risk is ongoing and genuinely contested. The FDA, CDC, and NIH have stated there is no conclusive causal evidence. The American Academy of Pediatrics recommends human milk — including pasteurized donor milk — for premature infants when the mother’s own milk is not available.

    What is not contested is the reporting record: the FDA received no death notifications from formula manufacturers going back to 2000, and Abbott’s own expert witness confirmed the company made no such reports.

    MedicalDaily Evidence Check

    • Investigation type: FOIA requests + court record analysis (KFF Health News, published July 2, 2026)
    • What it found: Zero FDA death notifications from formula manufacturers from January 2000 through the present; Abbott’s expert witness confirmed Abbott never made a single death report under any regulation for preterm formula
    • What it did not prove: That the formula directly caused the deaths — this remains contested between companies and plaintiffs
    • Regulatory context: FDA does not pre-approve infant formula; adverse event reporting for formula is largely at manufacturers’ discretion
    • What readers should know: The regulatory gap in formula death reporting is confirmed by FOIA records; families of premature infants have been fighting manufacturers in court without a government notification system creating an independent safety record

    Who Is Most Affected?

    This issue affects:

    • Parents of premature infants currently in NICUs who are receiving cow’s milk-based formula or fortifiers
    • Families who have experienced a premature infant death from NEC and may not know there is a reporting gap at the regulatory level
    • NICU clinicians and hospitals whose informed consent discussions about formula feeding may not have reflected the manufacturer’s internal awareness of NEC-related adverse events
    • Policymakers and advocates working on infant formula regulation reform

    Symptoms of NEC in Premature Infants

    Necrotizing enterocolitis typically develops in premature infants two to four weeks after birth, often around the time feedings begin. Warning signs that require immediate evaluation by the neonatal team include:

    • Sudden abdominal swelling or rigidity
    • Feeding intolerance after previously tolerating feeds
    • Bloody stool
    • Temperature instability
    • Lethargy or decreased responsiveness
    • Skin discoloration over the abdomen

    If your premature infant is in the NICU, ask the neonatal team specifically about NEC risk and what the protocol is for early detection.

    What You Can Do Now

    • If your premature infant is currently in a NICU, ask the neonatologist whether your baby is receiving human donor milk or cow’s milk-based formula, and what the facility’s protocol is for NEC monitoring.
    • Ask about your baby’s NEC risk based on gestational age and birth weight — infants born before 32 weeks and those under 1,500 grams face the highest risk.
    • Inquire about human milk availability at the facility. The American Academy of Pediatrics recommends human milk — including pasteurized donor milk — as the preferred nutrition for very premature infants.
    • If your premature infant previously suffered NEC while receiving cow’s milk-based formula, you may wish to consult a legal professional about your options. As of June 2026, active multidistrict litigation is proceeding in the Northern District of Illinois.
    • Report adverse events through the FDA’s MedWatch program if you believe a formula product contributed to a serious adverse event in your infant.

    Cost and Access: What Patients Should Know

    Human donor milk is more expensive than cow’s milk-based formula, and insurance coverage varies. NICU families should ask the billing department and the neonatology team about donor milk access and coverage. Many NICUs absorb donor milk costs for the highest-risk infants.

    For families who believe their infant was harmed by formula, legal consultations are typically offered at no upfront cost by firms handling NEC formula litigation. The Pancreatic Cancer Action Network NICHD page on NEC and infant feeding provides a recent scientific overview of the evidence.

    What Happens Next

    The KFF Health News investigation is expected to prompt renewed regulatory scrutiny of infant formula adverse event reporting requirements. The ongoing multidistrict litigation will produce additional bellwether trials in 2026 that may increase pressure on Abbott and Mead Johnson to consider broader settlements.

    Congress has shown some interest in strengthening formula safety oversight following the 2022 Abbott infant formula shortage and contamination recall. Whether the KFF Health News reporting prompts legislative action on adverse event reporting requirements remains to be seen.

    The Bottom Line

    The FDA received zero death notifications from infant formula manufacturers going back to the year 2000, according to FOIA records obtained by KFF Health News — confirmed by Abbott’s own expert witness, who testified the company never made a single such report for preterm formula. Approximately 2,300 premature infants died of NEC in the U.S. between 2017 and 2023. The combination of those two facts is not proof of causation — but it is a documented regulatory gap that left families fighting for accountability in court with no independent government safety record to draw on.

    Source link

  • The Heat Wave Could Cause Power Outages This Holiday Weekend: What to Do if Your Power Goes Out

    The Heat Wave Could Cause Power Outages This Holiday Weekend: What to Do if Your Power Goes Out

    The dangerous heat wave gripping the eastern United States is already knocking out power for hundreds of thousands of people, and emergency officials are warning that the worst of the heat and grid stress is not over.

    According to CNN reporting from July 3, more than 200,000 customers were without power Thursday evening as the heat wave intensified, including at least 19,000 Con Edison customers in the New York City metro area. The U.S. Department of Energy issued emergency grid orders allowing the PJM Interconnection to curtail data centers and waive power plant emissions limits through July 3 — measures that reflect how close to the edge the grid is operating.

    If your power goes out during this heat wave, the decisions you make in the first 30 to 60 minutes will determine whether the outcome is manageable or dangerous.

    Why This Matters

    Heat is the leading weather-related cause of death in the United States, accounting for more than 13,000 deaths since 2018 according to the CDC. What makes power outages during heat waves uniquely dangerous is the false sense of security that comes with being indoors.

    Without air conditioning, interior spaces can reach temperatures exceeding dangerous thresholds faster than most people expect. In an exterior temperature of 95°F, a home interior without cooling can reach body-temperature-threshold levels within one to two hours in upper floors. Upper stories and poorly ventilated rooms heat up the fastest. The tendency to wait and see whether power will be restored quickly is the most common behavioral pattern that turns a power outage into a medical emergency.

    What We Know So Far

    From AccuWeather reporting, CNN, and Department of Energy grid alerts as of July 3–4, 2026:

    • 200,000+ customers were without power Thursday evening, with more expected as the heat wave peaks
    • PJM demand forecast for July 2 was 166,147 MW — which would have exceeded the all-time PJM record of 165,563 MW set in 2006
    • Department of Energy emergency orders authorize PJM to require large data centers and energy consumers to switch to backup generators during grid stress events
    • 14 PJM states most at risk include Delaware, Illinois, Indiana, Kentucky, Maryland, Michigan, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Virginia, West Virginia, and Washington D.C.
    • Additional localized outages from equipment failures — transformers overheating in extreme conditions — can occur even without a grid-wide emergency
    • Con Edison has confirmed it is reducing voltage in parts of the Bronx and Manhattan to conserve energy during equipment repairs

    Where the Risk Is Highest

    The highest-risk areas for heat-related power outages this weekend are concentrated in the Mid-Atlantic and Northeast, where the combination of extreme heat, high humidity, dense urban heat island effects, and aging electrical infrastructure creates the most stress on the grid.

    Within cities, the highest-risk individuals are those in:

    • Upper-floor apartments without cross-ventilation
    • Older residential buildings with inefficient insulation that traps heat
    • Homes with window AC units (which require power to function) versus central air
    • Areas where Con Edison has already reduced voltage as of July 3

    The Action Plan: What to Do in the First 60 Minutes

    If your power goes out during this heat wave, public health officials and emergency management agencies recommend this action sequence — not a “wait and see” approach:

    Step 1 (Immediately): Move to the coolest part of your home. Heat rises. Move to the basement or lowest floor. Close blinds and curtains on south- and west-facing windows to block solar gain. Do not open windows while it is hotter outside than inside.

    Step 2 (First 15 minutes): Call or text your utility to report the outage. Do not assume the utility already knows. Con Edison and most major utilities have automated outage reporting by text or app. Reporting your outage gets you an estimated restoration time and gets your address into the repair queue.

    Step 3 (First 15 minutes): Check on the most vulnerable people in your household. Children under 4, adults 65+, people with chronic conditions, and people on temperature-sensitive medications need assessment first.

    Step 4 (30 minutes): Decide whether to shelter in place or leave. Do not wait for interior temperatures to reach dangerous levels before deciding. If outdoor temperatures are above 95°F and you expect power to be out for more than one to two hours, plan to leave for an air-conditioned location now. Options:

    • City cooling centers (find locations at your city’s 311 or emergency management website)
    • Public libraries
    • Malls and large retailers
    • A neighbor or family member with power
    • A movie theater

    Step 5 (Before leaving): Protect refrigerated medications. Insulins, some biologics, and other refrigerated medications can degrade rapidly at room temperature. Pack them in an insulated cooler with ice for the duration of the outage. Call a pharmacist for specific guidance on your medication’s temperature tolerance.

    What NYC Emergency Officials Say

    “Know where you will go to stay cool,” said NYC Mayor Zohran Mamdani in a statement as the heat emergency escalated. “A few minutes of planning now could help your family stay safe later.”

    “Anyone who loses power during extreme heat should avoid using generators indoors or near windows, doors or garages because of the risk of carbon monoxide poisoning,” AccuWeather reported, citing emergency management guidance.

    Con Edison advises customers to switch off or unplug major appliances while power is out to prevent potential damage when power is restored, and to leave one light switch in the “on” position so they know when power returns.

    What the Evidence Shows — and What It Does Not

    Heat stroke can develop within one to two hours of exposure to conditions where the body cannot maintain core temperature regulation — which happens faster in enclosed spaces without airflow than in open outdoor settings. This timeline is not theoretical: it reflects heat illness surveillance data from past heat wave fatalities.

    Localized equipment failures during heat waves are not predictable in advance. While the Department of Energy’s emergency orders reduce the risk of grid-wide blackouts, they do not prevent transformer failures caused by equipment overheating in specific neighborhoods.

    Who Faces the Greatest Risk?

    During a heat-related power outage:

    • Adults 65 and older living alone — especially in upper-floor apartments
    • Children under 4, who cannot regulate body temperature as effectively as adults
    • People with cardiovascular disease, diabetes, or kidney disease
    • People on certain medications including diuretics, beta-blockers, and antipsychotics that impair heat regulation
    • People who depend on powered medical equipment such as oxygen concentrators, home ventilators, or CPAP machines

    People on powered medical equipment should register with their utility as a “life support” or “medical baseline” customer. This registration provides priority restoration and advance notice of planned outages in many utility systems.

    Symptoms and Warning Signs to Watch For

    During a power outage in the heat, monitor yourself and household members for:

    Heat exhaustion:

    • Heavy sweating
    • Cold, pale, or clammy skin
    • Rapid, weak pulse
    • Nausea, dizziness, or fainting

    Move to a cool location immediately, drink cool water, and apply cool wet cloths to skin.

    Heat stroke — call 911 immediately:

    • High body temperature (above 103°F)
    • Hot, red, dry, or damp skin
    • Rapid, strong pulse
    • Confusion or unconsciousness

    Do not wait for heat stroke symptoms to “maybe get better.” Heat stroke is a life-threatening emergency.

    What You Can Do Now

    • Know your nearest cooling center before the power goes out. In New York: call 311 or use the LinkNYC kiosk map. In Philadelphia: phila.gov. In Washington D.C.: call 311. Do this now, while your phone is charged.
    • Charge all phones and medical device batteries now, while power is stable.
    • Do not use a generator indoors — ever. Not in the garage, not near any window or door. Carbon monoxide poisoning kills quickly and silently.
    • Keep your refrigerator closed. A closed refrigerator maintains safe food temperatures for approximately four hours without power. A full, closed freezer holds for 48 hours.
    • If power goes out for more than two hours with outdoor temps above 90°F, treat perishable foods as potentially unsafe. When in doubt, throw it out.
    • Reduce your home’s heat gain now by closing south-facing blinds and running appliances at night.

    Cost and Access: What Patients Should Know

    All cooling centers opened for the July 4 heat emergency are free, open to the public, and require no ID. Many are accessible to people with disabilities and permit service animals.

    Most utilities have emergency provisions that suspend service disconnections during declared heat emergencies. New York State’s Public Service Commission approved a comprehensive policy in March 2026 prohibiting utilities from terminating service for non-payment during extreme heat events. Contact your utility immediately if you are at risk of losing power due to non-payment during this heat emergency.

    What Happens Next

    Grid operators are closely monitoring demand through the July 4 weekend. The DOE emergency orders expired at 11:59 p.m. on July 3, but utilities may request additional emergency measures if demand remains elevated. Localized outages from equipment failures can occur at any time during extreme heat regardless of grid-wide emergency status. MedicalDaily will report on any significant grid events or expanded outage situations as this heat wave continues.

    The Bottom Line

    A heat-related power outage is a medical emergency in slow motion. The instinct to wait and see whether power returns quickly is the behavioral pattern that results in heat stroke fatalities. If your power goes out during this heat wave and is not restored within 30 to 60 minutes, act decisively: identify your cooling option, protect refrigerated medications, and leave if outdoor temperatures are above 95°F. Cooling centers in every major metro area affected by this heat wave are open, free, and ready to serve you right now.

    Source link

  • New World Screwworm Has Reached 16 U.S. Animals as Experts Say This Is Not an Isolated Incident

    New World Screwworm Has Reached 16 U.S. Animals as Experts Say This Is Not an Isolated Incident

    A flesh-eating parasite that the United States eradicated in 1966 has returned — and the 16 confirmed animal cases represent only the beginning of what veterinary experts and public health officials are working to contain.

    USDA’s Animal and Plant Health Inspection Service (APHIS) confirmed the first U.S. animal case on June 3, 2026, in a three-week-old calf in Zavala County, Texas, near the Mexico border. By the CDC’s most current accounting, 16 domestically acquired animal cases have been confirmed — spread across multiple Texas counties and Lea County, New Mexico, involving cattle, goats, and at least one dog.

    There have been no confirmed human infestations with New World Screwworm acquired in the United States. The Texas Animal Health Commission has quarantined a zone covering more than 20 Texas counties, and sterile fly releases are underway. But the public health challenge now is ensuring that ranchers, pet owners, and veterinarians understand what they are looking for — because what officials can count is likely only a fraction of what is actually out there.

    Why This Matters

    The New World Screwworm is not merely an economic pest. It is a uniquely dangerous parasitic fly because it targets living tissue — not dead or decaying material. The female fly lays eggs in any open wound, body opening, or skin abrasion on a warm-blooded animal. The larvae burrow into living flesh, producing compounds that attract more female flies, which lay more eggs, which produce more larvae. An infested, untreated animal can die within one week.

    The parasite affects cattle, sheep, goats, horses, deer, feral hogs, dogs, cats, and wildlife of all kinds. It can, in rare cases, infest humans — particularly through wounds or nasal passages. While human infestations in the United States are not expected under current conditions, the risk is not zero.

    The United States eradicated NWS domestically in 1966 using the sterile insect technique — a program that has been continuously maintained in Central America to prevent northward spread. The parasite’s reappearance now reflects the northward migration of screwworm populations from Mexico, where it was detected in Chiapas in November 2024 and has been spreading ever since.

    What We Know So Far

    From USDA APHIS, CDC, Texas Animal Health Commission, and the American Farm Bureau Federation:

    • First U.S. case: June 3, 2026 — a calf in Zavala County, Texas
    • Total confirmed U.S. animal cases: 16 domestically acquired (Texas and New Mexico)
    • Species affected: Cattle, goats, and at least one dog
    • Geographic spread: Multiple Texas counties, including Zavala, La Salle, Gillespie, and others; Lea County, New Mexico
    • Quarantine zone: More than 20 Texas counties covered by Texas Animal Health Commission quarantine orders; animals cannot be moved out of the zone without prior authorization
    • Sterile fly releases: More than 129 million sterile NWS flies released in the sterile fly release zone since February 2026
    • Human cases: No locally acquired human infestations in the U.S. confirmed
    • Food safety: USDA confirms the U.S. food supply is not at risk; NWS does not infest meat

    Where the Risk Is Highest

    The primary risk zone is South Texas — specifically the ranching and farming counties near the Mexico border. The Texas Animal Health Commission’s quarantine zone includes Bandera, Coke, Crockett, Edwards, Gillespie, Jim Hogg, Kerr, Kimble, La Salle, Medina, Pecos, Schleicher, Starr, Sutton, Terrell, Tom Green, Uvalde, Val Verde, Webb, Zapata, and Zavala Counties.

    A key vulnerability that concerns veterinary parasitologists is wildlife. White-tailed deer, exotic game species, and feral hogs are abundant throughout South Texas and can serve as NWS hosts. Unlike managed livestock, these populations cannot be routinely inspected. Any infested deer or hog can carry adult flies that then lay eggs on livestock or pets within the surrounding area.

    The confirmed dog case in Lea County, New Mexico — an area outside the primary South Texas detection zone — raises specific concerns about geographic spread through pet animals that may travel or that come into contact with infested wildlife.

    The American Farm Bureau Federation noted that the South Texas detection zone includes more than 160,000 sheep and goats, and many operations involve extensive rangeland where daily animal inspection is less common than on smaller farms.

    What Doctors and Experts Say

    “Report suspicions immediately,” said Bud Dinges, executive director of the Texas Animal Health Commission, in remarks following the first confirmed detection. “Quick notification leads to quick detection. A quick response will stop the pest from spreading.”

    USDA’s Rear Admiral Michael Schmoyer, APHIS Associate Administrator and Director of the NWS Directorate, said in June that the agency had deployed 8,000 fly traps at and near the U.S.-Mexico border and collected more than 58,000 fly samples and 19,000 wild animal samples — all of which had been negative for NWS at that time. That surveillance infrastructure is expanding as confirmed cases accumulate.

    Veterinary experts and livestock industry analysts have warned that confirmed cases represent only a subset of infestations that were both detected and reported. Animals in remote rangeland, wildlife, and feral hog populations are not systematically inspected, and infestations can progress rapidly before they are identified.

    What the Evidence Shows — and What It Does Not

    The epidemiological picture is confirmed: NWS is back in the United States. The current case count reflects only what has been detected and reported through the official surveillance system — which covers managed livestock that receive veterinary attention. Wildlife and large rangeland herds without daily inspection are almost certainly carrying more cases that have not been identified.

    Scaling sterile fly production to full eradication capacity — the method that successfully eliminated NWS from the United States in the 1960s — is expected to require 18 months to two years. That means U.S. ranchers and pet owners in the affected region face an extended containment period, not a quick resolution.

    MedicalDaily Evidence Check

    • Data source: USDA APHIS, CDC, Texas Animal Health Commission
    • Confirmed U.S. animal cases: 16 domestically acquired (Texas and New Mexico, as of most recent reporting)
    • Human cases: None confirmed in the U.S.
    • Available treatments: Multiple FDA Emergency Use Authorization (EUA)-approved products exist for cattle, horses, dogs, cats, and livestock; discuss with a veterinarian
    • Key limitation: Confirmed cases are an undercount; wildlife and large rangeland herds have limited inspection capacity
    • What readers should know: Livestock owners should inspect animals daily; pet owners in affected Texas counties and southern New Mexico should check for wounds; contact a veterinarian immediately if NWS is suspected

    Who Faces the Greatest Risk?

    • Livestock producers in South Texas and southern New Mexico counties — particularly those with cattle, sheep, and goats on extensive rangeland
    • Pet owners in the affected region, particularly owners of dogs and cats that spend time outdoors or that may have wound exposure
    • Wildlife (deer, feral hogs, exotic game) that serve as unmanageable host populations
    • Newborn animals, whose umbilical area is a common wound site for initial NWS infestation
    • Animals with any wound, cut, or body opening that has not been properly cleaned and treated

    Symptoms and Warning Signs to Watch For

    On livestock and pets:

    • Draining or enlarging wounds — especially wounds that do not heal normally
    • Signs of unusual distress or pain in an animal with a wound
    • Small, cream-colored larvae (maggots) visible in or around body openings — including the nose, ears, genitalia, and navel of newborns
    • Animals shaking their heads, rubbing against fences, or scratching excessively at wound areas
    • Foul-smelling discharge from a wound

    Infestations progress rapidly. An animal showing these signs should receive immediate veterinary attention. Without treatment, NWS can kill a full-grown animal within one week.

    What You Can Do Now

    • Inspect livestock and pets daily in affected Texas and New Mexico counties — particularly any animal with a wound, cut, or recent surgery.
    • Treat all wounds promptly with an approved insecticide or wound care product. Ask your veterinarian which FDA-authorized products are appropriate for your animals — multiple EUA products are now available for cattle, horses, dogs, and cats.
    • If you suspect NWS in an animal, do not wait. Contact your veterinarian immediately and report to the Texas Animal Health Commission (1-800-550-8242) or USDA APHIS.
    • Do not move animals out of the quarantine zone without authorization from TAHC.
    • Pet owners whose dogs or cats spend time outdoors in affected counties should inspect animals after outdoor time and keep wounds covered and treated.

    Cost and Access: What Patients Should Know

    The USDA Food Safety and Inspection Service confirms that the U.S. meat supply is not at risk — screwworm does not infest meat, and affected animals would be identified before entering commerce. Consumer food safety is not a concern in this outbreak.

    Veterinary treatment of confirmed NWS cases is covered by standard livestock health insurance in most cases. For producers concerned about coverage, the USDA’s Risk Management Agency provides livestock risk protection programs. Small-scale and hobby farm owners without commercial policies should contact their county Extension office for guidance on treatment costs and emergency assistance resources.

    What Happens Next

    USDA is continuing sterile fly releases, which represent the primary long-term eradication strategy. The 18-to-24-month timeline to full eradication capacity means this will be an ongoing management challenge throughout the rest of 2026 and into 2027.

    Updated case counts and quarantine zone maps are available at Screwworm.gov. MedicalDaily will report on any expansion of the quarantine zone, new confirmed cases in additional states, or any confirmed human infestations.

    The Bottom Line

    New World Screwworm has returned to the United States for the first time in 60 years. The 16 confirmed animal cases are almost certainly a fraction of the true infestation, and the multi-year eradication timeline means ranchers, pet owners, and veterinarians in affected regions of Texas and New Mexico face a sustained public health challenge. The food supply is safe. Human risk remains very low. But animal owners in the quarantine zone need to act now — inspect daily, treat wounds immediately, and report any suspected infestation without delay.

    Source link

  • The FDA Just Approved a Powerful Biologic for Children as Young as 6 with Severe Psoriasis or Psoriatic Arthritis

    The FDA Just Approved a Powerful Biologic for Children as Young as 6 with Severe Psoriasis or Psoriatic Arthritis

    Children as young as 6 years old with moderate-to-severe plaque psoriasis or active psoriatic arthritis now have access to one of the most effective biologics in dermatology and rheumatology, following an FDA approval announced June 26, 2026.

    AbbVie announced that the FDA has approved risankizumab (Skyrizi) for children 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and for active psoriatic arthritis in the same age group. A new 55 mg prefilled syringe was simultaneously approved to support weight-based dosing for patients weighing less than 40 kg, filling a critical gap in pediatric treatment access.

    Risankizumab is now the first and only interleukin-23 (IL-23) inhibitor approved in the United States for pediatric patients 6 years of age and older who weigh less than 40 kg with either plaque psoriasis or psoriatic arthritis.

    Why This Matters

    According to Drug Topics, approximately 30 percent of people who develop psoriasis first experience symptoms before age 18. For these patients, severe psoriatic disease can mean painful, visible skin lesions that affect school participation, social development, and mental health in addition to causing physical discomfort.

    Psoriatic arthritis in children — called juvenile psoriatic arthritis or psoriatic juvenile idiopathic arthritis — causes joint pain, swelling, and stiffness that can impair a child’s ability to walk, write, or participate in normal childhood activities. Before biologics in this class were available for children, treatment options were more limited, and some children were treated off-label with adult formulations in adult doses, which is not ideal from a pharmacokinetic standpoint.

    “Plaque psoriasis and psoriatic arthritis can affect much more than skin and joints — these conditions can shape daily life and disrupt important childhood experiences,” said Roopal Thakkar, MD, executive vice president of research and development at AbbVie.

    What We Know So Far

    Risankizumab is a humanized IgG1 monoclonal antibody that selectively blocks the p19 subunit of IL-23, a cytokine that drives the inflammatory cascade responsible for the skin plaques and joint inflammation in psoriatic disease. It was first approved for adults with moderate-to-severe plaque psoriasis in 2019 and has since received approvals for adult psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

    The pediatric approval is supported by data from the Phase 3 OptIMMize clinical trial program, which enrolled children and adolescents aged 6 through 17. Key findings from the trial:

    In adolescents aged 12 to 17: At week 16, 85.2 percent of risankizumab-treated patients achieved PASI75 (75% reduction in psoriasis severity), comparable to ustekinumab (85.7%). However, PASI100 (complete clearance) favored risankizumab at 40.7% versus 17.9% for ustekinumab.

    In children aged 6 to 11: Response rates at week 16 were high: PASI75 in 86.7%, PASI90 in 76.7%, and PASI100 (complete clearance) in 43.3%. Nearly all patients (90.0%) achieved a physician global assessment score of clear or almost clear.

    Durability: In adolescents who responded and continued treatment through week 52, approximately 95% maintained clear or almost clear skin — a strong durability finding for this age group.

    The safety profile in pediatric patients was consistent with the established adult safety profile, according to AbbVie and Contemporary Pediatrics.

    Who Qualifies for Skyrizi — Children and Dosing

    Age: 6 years and older

    Conditions: Moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy; OR active psoriatic arthritis

    Dosing by weight:

    • Children weighing less than 40 kg: 55 mg subcutaneous injection (new weight-based formulation)
    • Children weighing 40 kg or more: 150 mg subcutaneous injection (same as adult dosing)

    Administration schedule: An initial dose, followed by a dose 4 weeks later, then maintenance dosing every 12 weeks thereafter — the same schedule used in adults.

    The psoriatic arthritis approval for children 6 and older is supported by the OptIMMize psoriasis data plus population pharmacokinetic modeling from well-controlled adult PsA studies.

    What Doctors and Experts Say

    Amy S. Paller, MD, chair of dermatology and professor of pediatrics at Northwestern University Feinberg School of Medicine and a lead OptIMMize study investigator, called the approval significant: “These clinical responses, combined with weight-based dosing for younger patients, may help physicians better support a broad range of children living with these conditions.”

    Medscape’s analysis noted that this is the first IL-23 inhibitor to reach the under-40 kg pediatric population, distinguishing Skyrizi from other biologics in this class that have not yet reached this weight category in children.

    What the Evidence Shows — and What It Does Not

    MedicalDaily Evidence Check

    • Study type: Phase 3 randomized controlled trial (OptIMMize psoriasis program) — active-controlled in adolescents; single-arm open-label in children 6 to 11
    • Participants: Children and adolescents aged 6–17 with moderate-to-severe plaque psoriasis; PsA approval additionally supported by adult data plus PK modeling
    • Published in: Journal of Investigative Dermatology (conference data); FDA review completed June 26, 2026
    • What it found: High rates of PASI75, PASI90, and PASI100 at week 16 with durable responses through week 52
    • Key limitation: The psoriatic arthritis approval for children is partially supported by adult study data extrapolation through PK modeling rather than a dedicated pediatric PsA efficacy trial
    • Safety limitation noted: Detailed pediatric adverse event rates and serious adverse event rates were not publicly released in the press announcement

    What You Can Do Now

    • If your child has moderate-to-severe plaque psoriasis or psoriatic arthritis that has not been adequately controlled with topical therapies, ask your pediatric dermatologist or pediatric rheumatologist about risankizumab at your next appointment.
    • Before starting any biologic, standard screening includes tuberculosis testing, hepatitis B testing, and a review of current infections — discuss these with your child’s specialist.
    • The European Commission approved risankizumab for pediatric plaque psoriasis (ages 6 and up) on June 23, 2026 — just days before the U.S. approval — making this a global regulatory milestone for pediatric psoriatic disease.

    Cost and Access: What Patients Should Know

    Skyrizi is a biologic specialty medication. Insurance coverage and prior authorization requirements vary by plan. AbbVie has a patient support program — myAbbVie Assist — for eligible patients who need help with access or cost. Contact your specialty pharmacy or AbbVie’s patient support team for current assistance program details.

    The Bottom Line

    Skyrizi (risankizumab) is now FDA-approved for children 6 and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis — making it the first and only IL-23 inhibitor available for the under-40 kg pediatric population in the United States. Clinical trial data showed high rates of complete skin clearance in both adolescents and younger children, with durable responses through a year of treatment. Families of children with severe psoriatic disease should ask their pediatric specialist whether risankizumab is appropriate.

    Source link

  • How Same-Day IV Drip Services Are Changing the Future of Personalized Wellness

    How Same-Day IV Drip Services Are Changing the Future of Personalized Wellness

    Same-day IV drip services are reshaping how people approach wellness in a fast-moving world. Traditional health routines often require planning, travel, and waiting, which can discourage consistent care. In contrast, on-demand solutions are redefining expectations by bringing support directly to individuals when they need it most.

    One reason for this shift is the growing number of IV drip options available today. These options are designed to target specific concerns such as hydration, energy levels, or immune support, giving users more control over their wellness choices.

    Clarity around how the service works has also contributed to rising interest. A trained professional administers fluids, vitamins, and electrolytes through an intravenous line, allowing nutrients to enter the bloodstream without passing through the digestive system.

    In major metropolitan areas, NYC mobile IV drips reflect how urban lifestyles are driving demand for flexible care. Busy professionals and frequent travelers often prefer services that fit into their schedule rather than disrupt it.

    Cost planning has become easier as well. Many providers offer IV package deals, allowing people to commit to regular sessions while managing expenses more predictably.

    A Shift Toward Immediate Access in Wellness

    Healthcare and wellness services have undergone noticeable changes in recent years. People expect faster access to solutions that match up with their routines. Waiting days or weeks for an appointment no longer feels practical for those managing demanding schedules.

    Same-day IV drip services respond to this expectation by offering near-instant availability. This immediacy changes how people think about recovery and maintenance. Instead of postponing care, individuals can act as soon as they notice signs of fatigue or dehydration.

    This approach reflects a broader cultural shift. Convenience is no longer viewed as a luxury; it is becoming a standard expectation across industries, including wellness.

    Personalization Beyond Generic Solutions

    Personalized wellness has gained attention as people look for approaches that reflect their unique needs. Generic advice or one-size-fits-all products often fail to tend to specific concerns.

    Same-day IV drip services allow for a more individualized experience. Users can select treatments based on their current condition rather than following a fixed plan. This flexibility supports a more responsive approach to wellness.

    Personalization extends beyond the formula itself. Timing, location, and frequency can all be adjusted to match individual preferences. This level of customization creates a more engaging and practical experience.

    Time Efficiency as a Driving Influence

    Modern schedules leave little room for lengthy appointments. Time efficiency plays a big part in the adoption of same-day services. Individuals can receive care without sacrificing productivity or rearranging their day.

    Appointments are often scheduled around existing commitments. This allows users to continue working, relaxing, or managing responsibilities while receiving treatment. The ability to combine wellness with daily activities adds to the appeal.

    Reducing travel time is another advantage. Eliminating the need to commute to a clinic saves valuable time and reduces stress, making it easier to maintain consistency.

    Adapting to High-Performance Lifestyles

    High-performance environments demand consistent energy and focus. Professionals, entrepreneurs, and creatives often face long hours and high expectations. Maintaining physical and mental stamina becomes a priority in these settings.

    Same-day IV drip services meet these demands by offering targeted support when it is needed most. Instead of waiting for fatigue to build, individuals can respond quickly to changes in their energy levels.

    This proactive approach supports ongoing performance rather than reactive recovery. It fits well within lifestyles that prioritize productivity and efficiency.

    Expanding Access to Wellness Services

    Accessibility has long been a barrier in healthcare and wellness. Geographic limitations, scheduling conflicts, and availability can prevent individuals from searching for support.

    Same-day IV drip services reduce these barriers by bringing care directly to the user. This model expands access to individuals who may not have considered IV therapy in the past.

    The ability to receive treatment in a preferred setting also improves comfort. Familiar environments can make the experience more relaxed compared to traditional clinical spaces.

    Supporting Preventive Wellness Habits

    Preventive care has become a central focus in modern health discussions. Instead of waiting for symptoms to escalate, many individuals are adopting habits that support long-term well-being.

    Same-day IV drip services fit into this approach by offering a way to deal with minor concerns before they develop into larger issues. Hydration, nutrient support, and energy maintenance can all be managed proactively.

    The Importance of Technology in On-Demand Care

    Technology has played a big part in the rise of same-day services. Online booking systems, mobile apps, and real-time communication make it easier to schedule appointments quickly.

    These tools also allow users to explore different treatment options and select what meets their needs. Transparency in offerings helps people make the best possible decisions without unnecessary delays.

    Digital platforms have also improved coordination between providers and users. This efficiency supports the rapid response model that defines same-day services.

    Changing Expectations Around Recovery

    Recovery is no longer seen as something that requires extended downtime. Instead, people are looking for ways to maintain momentum while tending to their needs.

    Same-day IV drip services contribute to this shift by offering solutions that fit within active lifestyles. Users can continue their routines while receiving support, reducing the need for interruptions.

    This perspective reflects a broader change in how wellness is viewed. It is becoming an ongoing process rather than an occasional activity.

    Flexibility in Frequency and Commitment

    Flexibility is a defining feature of same-day IV drip services. Individuals can choose how often they receive treatments based on their goals and schedules.

    Some may opt for occasional sessions during periods of high demand. Others may incorporate regular treatments as part of a consistent routine. This adaptability allows users to customize their approach without rigid commitments.

    The availability of different scheduling options supports a number of preferences, making the service accessible to a broader audience.

    A New Direction for Personalized Wellness

    Same-day IV drip services represent a shift toward more responsive and individualized care. They match with the needs of modern lifestyles by offering convenience, flexibility, and targeted support.

    As expectations continue to progress, services that adapt to individual needs are likely to gain further attention. Personalized wellness is moving away from static routines and toward dynamic solutions that respond in real time.

    This transformation highlights a growing demand for options that fit smoothly into daily life. Same-day IV drip services are at the forefront of this movement, offering a new perspective on how wellness can be approached.

    Source link